This RCT (n=24) does a direct comparison, the first one in a double-blind trial, of MDMA, psilocybin, and 2C-B (10/20/30 mg) plus placebo in a six-period crossover in healthy subjects.
Randomised, triple-masked, placebo-controlled, six-period cross-over study in healthy volunteers comparing single oral doses of 2C-B (10, 20, 30 mg), MDMA (125 mg), psilocybin (25 mg) and placebo.
Aims are to characterise acute subjective, physiological and endocrine profiles and to compare empathogenic and classic psychedelic effects within the same subjects for basic science purposes.
Subjective effects peak 1–2 hours and are reported to last about 5 hours; outcomes include subjective ratings, vitals and endocrine measures.
Low dose 2C-B (10 mg) single-dose session.
4-bromo-2,5-dimethoxyphenethylamine (2C-B) 10 mg
Medium dose 2C-B (20 mg) single-dose session.
4-bromo-2,5-dimethoxyphenethylamine (2C-B) 20 mg
High dose 2C-B (30 mg) single-dose session.
4-bromo-2,5-dimethoxyphenethylamine (2C-B) 30 mg
Single oral dose MDMA (125 mg).
125 mg oral MDMA
Single oral dose psilocybin (25 mg).
25 mg oral psilocybin
Placebo (mannitol) control.
Placebo (mannitol)